(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Moldova says Russian drones violated airspace - 2This Week In Space podcast: Episode 187 — An Inspired Enterprise
- 3Exploring the Difficulties of Co-Nurturing: Individual Bits of knowledge
- 4Glamour Shots once ruled the mall. I went to one of the last ones standing.
- 5Amateur's Manual for Venture Strategies for Tenderfoots
- The most effective method to Guarantee Thorough Inclusion in Senior Protection.
- Vote in favor of Your #1 4\u00d74 SUVs
- Northern lights chances rise for Christmas as space weather remains unsettled
- The capacity to understand people on a profound level: Exploring Life's Intricacies
- South Korea to End Bear Bile Farming and Find New Homes for the 200 Bears Stuck in the Industry
- 'Dancing With the Stars' Season 34 finale: Who might win the mirror ball trophy? Where do the remaining contestants rank?
- US FDA grants market authorization to six on! PLUS nicotine pouch products
- US FDA declines to approve Corcept's drug for rare hormonal disorder
- Embrace the Outside: Exercises and Entertainment
